- Home
- SRG vs BDTX Comparison
SRG vs BDTX Comparison
Compare SRG & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | BDTX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.5M | 116.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SRG | BDTX |
|---|---|---|
| Price | $2.52 | $2.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 250.2K | ★ 868.1K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.39 | $1.93 |
| 52 Week High | $4.56 | $4.94 |
Technical Indicators
Market Signals| Indicator | SRG | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 43.75 |
| Support Level | $2.43 | $2.41 |
| Resistance Level | $2.80 | $2.79 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 43.28 | 20.67 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.